Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER plus /human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
ÌÇÐÄ´«Ã½
TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER plus /human epidermal growth factor receptor 2 (HER2)- advanced breast cancer Telli, M. L., Gawryletz, C. D., Wei, M., Patnaik, A., Lu, D. R., Mazzoletti, M., Valota, O., Parmar, S. S., Tan, W., Mukohara, T. LIPPINCOTT WILLIAMS & WILKINS. 2024View details for